Novozymes A/S (NSIS B.CO) Stock Price
Novozymes A/S Price
Revenue at Novozymes A/S has contracted by 13.4% per year over the past 9 years to 3.83 B EUR. Earnings per share have declined at 25.2% per year over the last 9 years. Novozymes A/S's net margin stands at 8.0%, down from 20.2% several years earlier. Novozymes A/S currently offers a dividend yield of about 7.14%. The payout ratio is around 80% of earnings. The dividend has grown at 3.2% per year over the past 9 years. Analysts set a median price target of 64.68 EUR, implying 15.5% above the current price. Of 23 analysts, 15 rate the stock a buy — an overall Buy consensus.
Novozymes A/S stock price
Novozymes A/S business model & stock analysis
Frequently asked questions about Novozymes A/S
The business model of Novozymes A/S is focused on providing sustainable solutions through the development and production of enzymes. Novozymes A/S offers a wide range of industrial enzymes used in various industries such as agriculture, bioenergy, food, and beverage. Their innovative enzymatic solutions help companies optimize processes, increase efficiency, and reduce environmental impact. Novozymes A/S aims to contribute to a more sustainable future by enabling their customers to produce more with less, ensuring a more efficient use of resources.
Novozymes A/S is primarily active in the industries of bioenergy, agriculture, and industrial biotechnology.
The main competitors of Novozymes A/S in the market include major players in the biotechnology and industrial enzymes industry. Some prominent competitors of Novozymes A/S are DuPont (now DowDuPont), DSM, BASF, and AB Enzymes. These companies operate in various sectors such as biofuels, textiles, food and beverages, detergents, and animal feed. Novozymes A/S competes through its extensive product portfolio, strong research and development capabilities, and global presence. By constantly innovating and offering sustainable solutions, Novozymes A/S strives to maintain its market position and provide added value to its customers in the biotech and industrial enzyme sectors.
Novozymes A/S, a Danish biotech company, has a rich and notable history. Established in 2000 as a spin-off from Novo Nordisk, Novozymes quickly became a leader in industrial enzymes and microorganisms. With more than 90 years of experience, the company has pioneered innovative solutions in bioenergy, food and beverages, agriculture, and various other industries. Novozymes focuses on sustainable practices, aiming to address global challenges such as climate change, resource scarcity, and waste reduction. Guided by their vision of "Together, we find biological answers for better lives in a growing world," Novozymes continues to contribute significantly to the advancement of bio-based solutions worldwide.
Novozymes A/S has achieved several significant milestones throughout its history. The company, a world leader in biological solutions, introduced its first microbial enzyme back in 1941, marking a breakthrough in the field. In 2000, Novozymes became the world's largest producer of industrial enzymes and continues to maintain its leading position. Furthermore, the company has made remarkable strides in sustainable solutions, aiming to combat climate change and reduce reliance on fossil fuels. Novozymes' innovative enzyme technologies have revolutionized various industries, such as bioenergy, agriculture, and household care, fostering a more sustainable future. The company's commitment to research and development has contributed to its continuous growth and recognition as a global frontrunner.
Novozymes A/S is primarily present in multiple countries and regions across the globe. The company has a strong presence in its home country, Denmark, and has expanded its operations to other European countries such as Germany, Sweden, and France. Additionally, Novozymes A/S has a significant presence in North America, with offices and facilities located in the United States and Canada. The company also serves customers in regions like Asia-Pacific, including countries such as China, Japan, and India. With its global footprint, Novozymes A/S is able to cater to a wide range of markets and industries worldwide.
Novozymes A/S represents values of sustainability, innovation, and collaboration. As a leading biotechnology company, Novozymes focuses on delivering biological solutions to industries worldwide. Their corporate philosophy centers around harnessing the power of nature's enzymes to create sustainable solutions for a wide range of global challenges. Novozymes aims to enable businesses to optimize their processes while reducing their environmental impact. By working together with customers, partners, and stakeholders, Novozymes strives to create a more sustainable future. With a strong commitment to research and development, Novozymes continues to drive innovation and contribute to a more sustainable world.
Analysts currently set an average price target of 64.71 EUR for the Novozymes A/S stock (median: 64.68 EUR), implying +15.5 % versus the latest price. The consensus is based on 23 analyst ratings.
23 analysts currently rate the Novozymes A/S stock: 15 recommend buying, 5 holding and 3 selling. For 2026, analysts expect Novozymes A/S to generate revenue of 4.49 B EUR and earnings per share of 2.03 EUR.
The Novozymes A/S share (NSIS B.CO) is listed on 10 stock exchanges, including: London (0Q4U.L), SIX (Zürich) (NZYMB.SW), XETRA (NZM2.DE), Frankfurt (NZM2.F), München (NZM2.MU), Düsseldorf (NZM2.DU), Wien (NZYM.VI), Kopenhagen (NZYM-B.CO).
Novozymes A/S is a Danish company specializing in the production of enzymes. The company's business model is based on the manufacture and marketing of enzymes and microorganisms for improving industrial processes and products in the food, biofuels, and detergent sectors. It is divided into three main business areas: enzymes, microorganisms, and bioagriculture. Within the enzyme division, Novozymes offers a variety of enzymes used in various industries such as textiles, paper, food and beverage, and biofuel production. The microorganism division focuses on developing and marketing microorganisms to improve industrial processes and products, including treatment of sludge and waste, wastewater cleaning, and livestock health. The bioagriculture division concentrates on developing biological solutions to increase crop yields, offering tailored products for specific crops and growing conditions. Novozymes' business model aims to provide customers with innovative solutions to improve their processes and products while reducing costs and environmental impact. Research and development play a significant role in continuously developing new products and technologies to enhance efficiency and sustainability. The company invests approximately 13% of its revenue annually in research and development to strengthen its leadership in enzymatic solutions. Overall, Novozymes focuses on developing and marketing enzymes, microorganisms, and biological solutions to enhance industrial processes and products, working closely with customers and partners to develop customized solutions tailored to their specific needs.
The expected revenue of Novozymes A/S is 4.49 B EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Novozymes A/S is 934.53 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Novozymes A/S is currently 27.55. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Novozymes A/S stock.
The price-to-sales ratio (P/S) of Novozymes A/S is currently 5.74. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Novozymes A/S stock.
The Eulerpool Quality Score for Novozymes A/S is 4/10.
The ISIN of Novozymes A/S is DK0060336014. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Novozymes A/S is A1JP9Y. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Novozymes A/S is NSIS B.CO. The ticker symbol is used to trade Novozymes A/S shares on the stock exchange.
Novozymes A/S stock
Novozymes A/S Peer Group
Novozymes A/S Ticker
Novozymes A/S FIGI
All fundamentals and in-depth analysis of Novozymes A/S
Our stock analysis for Novozymes A/S stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Novozymes A/S. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.